| Primary information |
|---|
| OV_ID | OV_600 |
| Virus Name | Alphavirus |
| Strain | M1 |
| Virus type | RNA |
| Virus family | Togaviridae |
| Modification in virus genome | None |
| Virus alone | No |
| Virus in combination iwth drug/radiation | Viral strain in combination with ESI-09 and with H89(10 μM) |
| Immune gene induction in virus genome | No |
| Source of cell line | ATCC |
| Origin of cell line | Human pancreatic ductal adenocarcinoma cell line |
| Cell line | Capan-1 |
| Concentration of cell line | 4000 |
| In-vitro toxicity | NA |
| Assay | MTT assay |
| In-vitro virus concentration | 0.1 PFU/cell |
| In-vitro result | 75% cancer cell viability at 72 hours post-infection |
| Model organism | No |
| In-vivo virus concentration | No |
| In-vivo toxicity | NA |
| In-vivo result | No response |
| Mode of delivery | NA |
| Pathway induction | ESI-09 abrogates the activities of Caspase-3/9/8 induced by H89/M1 combination treatment. |
| Immunogenic effect | M1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89 |
| Clinical trial | NA |
| PMID | 27374176 |